TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 359-365

  Lotan, Tamara L ^a   Toubaji, Antoun ^a   Albadine, Roula ^a   Latour, Mathieu ^a   Herawi, Mehsati ^a   Meeker, Alan K ^a   Demarzo, Angelo M ^a   Platz, Elizabeth A ^a,b   Epstein, Jonathan I ^a   Netto, George J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Ductal adenocarcinoma; Endometrioid; Gene fusion; Prostatic adenocarcinoma; TMPRSS2 ERG

Indexed keywords

PROTEIN TMPRSS2; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FUSION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC DUCTAL ADENOCARCINOMA;

CARCINOMA, ACINAR CELL; CARCINOMA, DUCTAL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 61349195117     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.236     Document Type: Article

References (27)

1. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 1986;57:111-119.
2. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 1999;23:781-785.
3. Melicow MM, Pachter MR. Endometrial carcinoma of proxtatic utricle (uterus masculinus). Cancer 1967;20:1715-1722.
4. Greene LF, Farrow GM, Ravits JM, et al. Prostatic adenocarcinoma of ductal origin. J Urol 1979;121:303-305.
5. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 1985;9:595-609.
6. Christensen WN, Steinberg G,Walsh PC, et al. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 1991;67:2118-2124.
7. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999;23:1471-1479.
8. Orihuela E, Green JM. Ductal prostate cancer: contemporary management and outcomes. Urol Oncol 2008;26:368-371.
9. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
10. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
11. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
12. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-5108.
13. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14:3380-3385.
14. Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 1996;29:11-19.
15. Epstein JI, Allsbrook WC, Amin MB, et al. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006;13:57-59.
16. Epstein JI, Netto GN. Biopsy Interpretation of the Prostate 2nd ed Lippincott, Williams & Wilkins: Philadelphia, PA, 2008.
17. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
18. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
19. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695.
20. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-4599.
21. Gopalan A, Leversha M, Satagopan JM, et al. Increased copy number of TMPRSS2-ERG fusion, but not translocation alone, is associated with aggressive disease in patients treated by prostatectomy. Mod Pathol 2008;21:158A.
22. Fine SW, Gopalan A, Al-Ahmadie HA, et al. Does TMPRSS2-ERG gene fusion status in prostate cancer correlate with Gleason score? Mod Pathol 2008;21:156A.
23. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008;105:2105-2110.
24. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-188.
25. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008;27:5348-5353.
26. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351.
27. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007;20:921-928.